Risteys · CD2_INSITU_MELANOMA_EYELID

Endpoint definition steps	FinnGen
Phenotype data
1. Apply sex-specific rule None	-
2. Check conditions None
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — D03.1& Cause of death: ICD-10 — D03.1& 2 out of 7 registries used, show all original rules.	-
4. Check minimum number of events None	-
5. Include endpoints None	-
6. Filter based on genotype QC (FinnGen only) None	-

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	21	11	10
Unadjusted period prevalence (%)	0.00	0.00	0.00
Median age at first event (years)	64.56	65.07	64.00

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(40768804) Tissue Pathology biopsy report

5.58

3.55

3.9

1.5

—

(3002256) Pathology report gross observation

4.68

1.83

2.0

1.1

—

(3013512) EKG study

2.75

1.35

3.7

4.2

—

(40761511) CBC panel - Blood by Automated count

184

+∞

0.85

15.8

12.2

—

(3037467) Urinalysis macro (dipstick) panel - Urine

126

2.13

0.78

5.6

4.2

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

2.06

0.76

3.2

3.9

—

(3016771) Amylase [Enzymatic activity/volume] in Serum or Plasma

2.02

0.74

2.5

1.8

u/l

54.6

65.5

—

(40758558) Short blood count panel - Blood

1.99

0.65

7.7

4.4

—

(3027238) Thyroperoxidase Ab [Units/volume] in Serum or Plasma

0.00

0.63

0.0

1.0

—

125.0

—

(1761868) Lipid panel - Serum or Plasma

1.64

0.53

2.6

3.4

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

1.53

0.46

2.7

4.3

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

0.00

0.42

0.0

1.3

—

(3015399) Transferrin receptor.soluble [Mass/volume] in Serum or Plasma

1.55

0.39

1.3

1.9

mg/l

3.4

2.7

—

(3003694) ABO and Rh group [Type] in Blood

1.46

0.38

1.3

1.4

—

(36304419) Bacteria [Presence] in Urine

1.60

0.37

3.4

2.7

—

(3041096) Erythrocytes [Presence] in Urine by Automated

1.56

0.37

2.1

3.7

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

1.37

0.25

2.4

4.0

—

(3044640) Blood type and Crossmatch panel - Blood

1.39

0.23

3.0

2.3

—

(46235759) Influenza virus B RNA [Presence] in Nasopharynx by NAA with probe detection

0.00

0.22

0.0

1.0

—

(36660697) Celiac disease serology panel - Serum

0.00

0.22

0.0

1.5

—

(3044254) Respiratory syncytial virus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.22

0.0

1.0

—

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

0.00

0.22

0.0

9.2

—

0.7

—

(3014007) Fractional oxyhemoglobin in Arterial blood

0.00

0.22

0.0

9.2

—

95.2

—

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

0.00

0.22

0.0

9.2

—

1.3

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.31

0.21

3.4

3.8

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

1.39

0.20

2.5

2.2

—

(3015736) pH of Urine

1.28

0.20

2.4

3.9

—

(3019150) Specific gravity of Urine by Refractometry

1.25

0.11

2.2

4.4

—

1.0

—

(3023368) Bacteria identified in Blood by Culture

1.21

0.11

4.6

3.8

—

(3003338) MCHC [Mass/volume]

145

0.90

0.09

19.5

18.3

g/l

332.2

331.8

0.05

145

(3029187) Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma

0.82

0.09

3.5

3.2

ng/l

657.3

985.1

—

(3044889) 12 lead EKG panel

130

0.82

0.09

4.3

4.5

—

(3013826) Glucose [Moles/volume] in Serum or Plasma

110

1.21

0.09

2.9

4.3

mmol/l

6.3

6.9

0.73

103

(3032155) Metanephrine Free [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3032035) Polymorphonuclear cells/100 leukocytes in Blood

0.00

0.0

4.4

—

55.8

—

(3010566) Parathyrin.intact [Moles/volume] in Serum or Plasma

0.00

0.0

5.4

—

(3029379) Protein.monoclonal band 4 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.2

—

0.0

—

(3028286) Albumin [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.2

—

33.1

—

(3029338) Protein.monoclonal band 3 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.2

—

0.0

—

(3030408) 3-Methoxytyramine [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3029713) Protein.monoclonal band 1 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.2

—

0.0

—

(3018405) Lactate [Moles/volume] in Arterial blood

0.00

0.0

10.6

—

1.0

—

(3035797) Protein.monoclonal band 2 [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.2

—

0.0

—

(3023419) Bacteria identified in Sputum by Culture

0.00

0.0

1.6

—

(3009340) Metanephrine [Moles/volume] in Serum or Plasma

0.00

0.0

1.2

—

(3030905) Polymorphonuclear cells [#/volume] in Blood

0.00

0.0

1.4

—

4.8

—

(40760847) Basement membrane Ab [Titer] in Serum by Immunofluorescence

0.00

0.0

1.5

—

(3015322) Alpha 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis

0.00

0.0

1.2

—

2.6

—

(4094501)

0.00

0.0

1.3

—

(3036489) Thrombin time

0.00

0.0

1.7

—

20.8

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.0

1.3

—

(3005322) IgE [Units/volume] in Serum or Plasma

0.00

0.0

1.8

—

183.1

—

(3052851) Hemolysis interference index of Serum or Plasma

0.00

0.0

2.8

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.0

1.6

—

196.3

—

(3025839) Triglyceride [Moles/volume] in Serum or Plasma

0.84

0.00

1.8

1.5

mmol/l

1.1

1.2

—

(3004383) Neutrophil cytoplasmic Ab.classic [Titer] in Serum by Immunofluorescence

0.00

0.0

1.5

—

(3002434) Lupus erythematosus deoxynucleoproteins IgG Ab [Units/volume] in Serum by Immunoassay

0.00

0.0

1.2

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.00

0.0

1.0

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.0

1.8

—

(21494755) Public health laboratory ask at order entry panel

0.00

0.0

1.2

—

(3030467) Casts [#/volume] in Urine by Automated count

0.97

0.00

3.8

3.1

e6/l

0.0

0.6

—

(3001122) Ferritin [Mass/volume] in Serum or Plasma

0.98

0.00

2.7

3.2

ug/l

77.6

131.4

—

(42870588) Differential panel, method unspecified - Blood

1.00

0.00

5.5

5.9

—

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

0.00

0.0

1.7

—

85.9

—

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

0.00

0.0

1.1

—

2.9

—

(3021901) Oxygen saturation in Capillary blood

0.00

0.0

2.2

—

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: CD2_INSITU_MELANOMA_EYELID_EXALLC – Melanoma in situ of eyelid, including canthus

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

NAME	CD2_INSITU_MELANOMA_EYELID_EXALLC
CONTROL_EXCLUDE	C3_CANCER\|C3_CANCER_WIDE
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	D031
HD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	D031
COD_ICD_9	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

≡ Risteys

FG R12 + FR

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Melanoma in situ of eyelid, including canthus

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

All original rules

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

-FinnGen-

Key figures

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Relationships between endpoints